Breakthrough in Cancer Treatment: SynAffix and Innovent Bio Initiate Phase III Clinical Trial for Claudin18.2 ADC

In a significant development in the field of cancer therapeutics, Innovent Bio, in collaboration with SynAffix, has commenced a Phase III clinical trial for their novel drug, IBI343. The trial aims to evaluate the efficacy of IBI343, an antibody-drug conjugate (ADC), in the treatment of HER2-negative gastric cancer patients who are positive for Claudin18.2. This groundbreaking trial marks the first-ever Phase III clinical study for a Claudin18.2 ADC worldwide.

The Clinical Trial:

Registered on the Clinicaltrials.gov website on February 2, 2024, the Phase III clinical trial of IBI343 plans to enroll 450 patients diagnosed with gastric cancer. The trial will compare the effectiveness of IBI343 with standard chemotherapy. The preliminary results are expected to be available in May 2026. IBI343 adopts a differentiated design, utilizing ADC technology developed in collaboration with SynAffix. The ADC employs Glycan-mediated site-specific conjugation with a drug-to-antibody ratio (DAR) of 4. The antibody used in IBI343 is highly internalizing and has undergone FcSilence mutation, leading to enhanced anti-tumor activity. Early clinical observations have demonstrated promising tumor response and excellent tolerability, even at doses up to 10mg/kg. Innovent Bio considers ADC as a strategic focus in the field of oncology.

Competition in Claudin18.2 Targeted Therapy:

The Claudin18.2 target is one of the most fiercely contested in domestic research and development. In the realm of monoclonal antibodies, companies such as Chuangsheng Group, Mingji Biotechnology, and Ausgenex have already entered Phase III clinical trials.Meanwhile, in the domain of ADCs, Innovent Bio has taken the lead by initiating Phase III clinical trials for IBI343. Additionally, Claudin18.2 ADC developed by Konoa/Lepu has entered into an authorized collaboration with AstraZeneca, involving a staggering upfront payment of $63 million. This signifies the intense competition among monoclonal antibodies, bispecific antibodies, ADCs, and CAR-T therapies targeting Claudin18.2.

The initiation of the Phase III clinical trial for Innovent Bio's IBI343 represents a significant breakthrough in cancer treatment. With its differentiated design and superior anti-tumor activity, IBI343 holds immense promise for HER2-negative gastric cancer patients positive for Claudin18.2. This pioneering ADC, developed in collaboration with SynAffix, has the potential to revolutionize the field of oncology and improve patient outcomes. The ongoing competition among various pharmaceutical companies underscores the importance of Claudin18.2 as a highly sought-after target in the pursuit of more effective cancer therapies.